Similar Papers

Paper Title
Journal
Date
Author
Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study
Takaaki Ono ... Naoto Takahashi
Blood | VOL. 138
Takaaki Ono, et. al.Takaaki Ono ... Naoto Takahashi
05 Nov 2021
Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial
Chikashi Yoshida ...
Blood | VOL. 138
Chikashi Yoshida, et. al.Chikashi Yoshida ...
05 Nov 2021
Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial)
Hirohiko Shibayama ... Yuzuru Kanakura
Blood | VOL. 128
Hirohiko Shibayama, et. al.Hirohiko Shibayama ... Yuzuru Kanakura
02 Dec 2016
View more papers

More From: Blood

Paper Title
Journal
Date
Author
How I approach pharmacological thromboprophylaxis in children.
Anthony A Sochet ... Neil A Goldenberg
Blood | VOL. -
Anthony A Sochet, et. al.Anthony A Sochet ... Neil A Goldenberg
03 Feb 2025
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
A novel therapy with a rational design for AML.
Maria L Amaya
Blood | VOL. 145
Maria L AmayaMaria L Amaya
30 Jan 2025
For how long has this problem been there?
Niccolò Bolli ... Matteo Claudio Da Vià
Blood | VOL. 145
Niccolò Bolli, et. al.Niccolò Bolli ... Matteo Claudio Da Vià
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.